Cargando…
Receptor Tyrosine Kinases and Inhibitors in Lung Cancer
Lung cancer is a deadly disease with high mortality and morbidity. Most cases of lung cancer are due to non-small cell carcinoma, with 16% of cases being small cell carcinoma. The biology at a cellular level is of interest at many levels. Knowing cellular pathways helps to further enhance our knowle...
Autores principales: | Pisick, Evan, Jagadeesh, Simha, Salgia, Ravi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
TheScientificWorldJOURNAL
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5956372/ https://www.ncbi.nlm.nih.gov/pubmed/15349502 http://dx.doi.org/10.1100/tsw.2004.117 |
Ejemplares similares
-
A Closer Look at EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer through the Lens of Precision Medicine
por: Sattler, Martin, et al.
Publicado: (2023) -
Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer
por: Ferguson, Benjamin D., et al.
Publicado: (2015) -
Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer
por: Kanteti, Rajani, et al.
Publicado: (2014) -
Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications
por: Quintanal-Villalonga, A., et al.
Publicado: (2016) -
Anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer
por: Vavalà, Tiziana, et al.
Publicado: (2019)